Cargando…

Preclinical evaluation of [(58m)Co]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer

Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a promising target for radionuclide therapy. Auger electron-emitting radionuclides are well suited for targeted radionuclide therapy if they can be delivered close to the DNA of the targeted cells. This preclinical st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baun, Christina, Dam, Johan Hygum, Hildebrandt, Malene Grubbe, Ewald, Jesper Dupont, Kristensen, Bjarne Winther, Gammelsrød, Vigga Sand, Olsen, Birgitte Brinkmann, Thisgaard, Helge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620164/ https://www.ncbi.nlm.nih.gov/pubmed/37914790 http://dx.doi.org/10.1038/s41598-023-43429-8

Ejemplares similares

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery
por: Thisgaard, Helge, et al.
Publicado: (2016)

(68)Ga, (44)Sc and (177)Lu-labeled AAZTA(5)-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
por: Sinnes, Jean-Philippe, et al.
Publicado: (2020)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Perspective of Patients With Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed Methods Study
por: Baun, Christina, et al.
Publicado: (2020)

Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
por: Holm, Jorun, et al.
Publicado: (2020)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

PSMA-617 inhibits proliferation and potentiates the (177)Lu-PSMA-617-induced death of human prostate cancer cells
por: Zhao, Yi, et al.
Publicado: (2023)

Design, Synthesis, Computational, and Preclinical Evaluation of (nat)Ti/(45)Ti-Labeled Urea-Based Glutamate PSMA Ligand
por: Søborg Pedersen, Kristina, et al.
Publicado: (2020)

Cisplatin-Resistant CD44(+) Lung Cancer Cells Are Sensitive to Auger Electrons
por: Madsen, Karina Lindbøg, et al.
Publicado: (2022)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
por: Thisgaard, Helge, et al.
Publicado: (2021)

Facile transmetallation of [Sb(III)(DOTA)](−) renders it unsuitable for medical applications
por: Chen, Catherine, et al.
Publicado: (2022)

A randomised trial of [(18)F]PSMA‐1007‐PET/CT versus NaF‐PET/CT for staging primary prostate cancer: A trial protocol
por: Buch‐Olsen, Karen Middelbo, et al.
Publicado: (2023)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule
por: Garousi, Javad, et al.
Publicado: (2017)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
por: Wang, Guochang, et al.
Publicado: (2022)

Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
por: Rosar, Florian, et al.
Publicado: (2021)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

Preparation of (177)Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House
por: Guleria, Mohini, et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
por: Gosewisch, Astrid, et al.
Publicado: (2018)

Spectro Auger
Publicado: (1995)

Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
por: Hansen, Jeanette Ansholm, et al.
Publicado: (2021)

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
por: Pelletier, Karyne, et al.
Publicado: (2020)

Hematological Toxicity in Mice after High Activity Injections of (177)Lu-PSMA-617
por: Kristiansson, Amanda, et al.
Publicado: (2022)

(64)Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model
por: Han, Xue-Di, et al.
Publicado: (2017)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

(68)Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
por: Zhang, Jiaying, et al.
Publicado: (2022)

The Pierre Auger project
por: Mantsch, P M
Publicado: (1996)

The Pierre Auger Observatory
por: Swain, J D
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_79o8afkh9ukfqkt2sa79inr37n